Email this article Clinical assessment of primalan (mequitasine) in allergology
- Authors: Ilyina NI1, Latysheva ТV1, Varfolomeeva MI1
-
Affiliations:
- Государственный научный центр - Институт иммунологии Минздрава РФ
- Issue: Vol 78, No 4 (2003)
- Pages: 58-60
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/29368
- ID: 29368
Cite item
Full Text
Abstract
Aim. To study efficacy of primalan (mequitasine) in the treatment of allergic rhinoconjunctivitis and chronic recurrent urticaria.
Material and methods. The study included 140 patients. Of them, 60 patients had allergic rhinitis, 80 patients had chronic recurrent urticaria. All the patients received primalan (mequitasin) in a dose 10 mg/day (5 mg twice daily or a single dose 10 mg). The disease symptoms and side effects of primalan were assessed for 28 days of the treatment.
Results. Primalan (mequitasin) proved to be highly effective against allergic rhinitis (good and very good response - 76%, satisfactory - 20%) and chronic recurrent urticaria (the response in 90% patients). Good primalan tolerance was reported. Side effects were moderate and did not require the drug withdrawal (sleepiness in 6.6%, dryness of the mucosa in 5%).
Conclusion. Primalan (mequitasin) can be recommended for wide application in therapy of allergic rhinitis and chronic recurrent urticaria.
Material and methods. The study included 140 patients. Of them, 60 patients had allergic rhinitis, 80 patients had chronic recurrent urticaria. All the patients received primalan (mequitasin) in a dose 10 mg/day (5 mg twice daily or a single dose 10 mg). The disease symptoms and side effects of primalan were assessed for 28 days of the treatment.
Results. Primalan (mequitasin) proved to be highly effective against allergic rhinitis (good and very good response - 76%, satisfactory - 20%) and chronic recurrent urticaria (the response in 90% patients). Good primalan tolerance was reported. Side effects were moderate and did not require the drug withdrawal (sleepiness in 6.6%, dryness of the mucosa in 5%).
Conclusion. Primalan (mequitasin) can be recommended for wide application in therapy of allergic rhinitis and chronic recurrent urticaria.
About the authors
N I Ilyina
Государственный научный центр - Институт иммунологии Минздрава РФМосква; Государственный научный центр - Институт иммунологии Минздрава РФ
Т V Latysheva
Государственный научный центр - Институт иммунологии Минздрава РФМосква; Государственный научный центр - Институт иммунологии Минздрава РФ
M I Varfolomeeva
Государственный научный центр - Институт иммунологии Минздрава РФМосква; Государственный научный центр - Институт иммунологии Минздрава РФ
References
- Клиническая аллергология: Руководство для практических врачей / Под ред. Р. М. Хаитова. М.: МЕДпресс-информ; 2002.
- Howarth P. H. Assessment of anihistamine efficacy and potency. Clin. Exp. Allergy 1999; 29 (suppl. 3): 87-97.
- Simons F. E. HI-receptor antagonist. Comparative tolerability and safety. Drug Saf. 1994; 10: 350-380.
- Uzan A., Le Fur G. A propos de la mequitazine, un novel antiallergique. Gaz. Med. Fr. 1977; 84 (28): 3059-3063.
Supplementary files
